| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1034618149 |
| P356 | DOI | 10.1038/LEU.2009.251 |
| P698 | PubMed publication ID | 20010622 |
| P50 | author | Kjeld Schmiegelow | Q63437076 |
| P2093 | author name string | M Hellebostad | |
| E Forestier | |||
| M Heyman | |||
| M Taskinen | |||
| S Söderhäll | |||
| J Kristinsson | |||
| Nordic Society of Paediatric Haematology and Oncology | |||
| P2860 | cites work | Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. | Q64934003 |
| Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL | Q73916900 | ||
| Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia | Q74192288 | ||
| Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region | Q74267648 | ||
| Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome | Q77601838 | ||
| Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye | Q78385056 | ||
| The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations | Q80123655 | ||
| Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol | Q80218913 | ||
| Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping | Q80419584 | ||
| Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia | Q80962315 | ||
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia | Q29614324 | ||
| Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia | Q35925016 | ||
| Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature | Q36996304 | ||
| Allogeneic transplantation for childhood ALL. | Q36997720 | ||
| Minimal residual disease in acute lymphoblastic leukemia | Q37077352 | ||
| Current management and challenges of malignant disease in the CNS in paediatric leukaemia | Q37097413 | ||
| Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study | Q37234604 | ||
| Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia | Q37319370 | ||
| Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study | Q37502607 | ||
| Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis | Q39792851 | ||
| Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children | Q40622023 | ||
| Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia | Q40961746 | ||
| Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study | Q43299909 | ||
| Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. | Q43676402 | ||
| Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study | Q43981086 | ||
| High incidence of the ETV6/RUNX1 fusion gene in paediatric precursor B-cell acute lymphoblastic leukaemias with trisomy 21 as the sole cytogenetic change: a Nordic series of cases diagnosed 1989-2005. | Q44049097 | ||
| A population-based study of childhood acute lymphoblastic leukemia diagnosed from July 1981 through June 1985 in the five Nordic countries. Incidence, patient characteristics and treatment results | Q44066261 | ||
| Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia | Q44381583 | ||
| Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia | Q44497845 | ||
| Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation | Q44749261 | ||
| Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia | Q46398603 | ||
| Dic(9;20)(p13;q11) in childhood acute lymphoblastic leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids | Q46492423 | ||
| High incidence of secondary brain tumours after radiotherapy and antimetabolites. | Q48163138 | ||
| Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). | Q50670506 | ||
| A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. | Q53232081 | ||
| Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). | Q53589047 | ||
| Acute lymphoblastic leukaemia | Q56722375 | ||
| Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival | Q61643142 | ||
| P433 | issue | 2 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 345-354 | |
| P577 | publication date | 2009-12-10 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia | |
| P478 | volume | 24 |
| Q37166753 | A 50-year journey to cure childhood acute lymphoblastic leukemia |
| Q48112900 | A Bayesian CUSUM plot: Diagnosing quality of treatment. |
| Q26866379 | A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm |
| Q49843440 | A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia |
| Q38674589 | A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. |
| Q35061962 | Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment |
| Q37429718 | Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group |
| Q90472968 | Adrenal function after induction therapy for acute lymphoblastic leukemia in children short: adrenal function in ALL |
| Q43833498 | Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008. |
| Q39027835 | Antibiotic use during infectious episodes in the first 6 months of anticancer treatment-A Swedish cohort study of children aged 7-16 years |
| Q38848749 | Arthritis as presenting manifestation of acute lymphoblastic leukaemia in children |
| Q64066039 | Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models |
| Q38036389 | Asparaginase-associated pancreatitis in children |
| Q51620499 | Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. |
| Q33729728 | Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. |
| Q34764504 | Biology, risk stratification, and therapy of pediatric acute leukemias: an update |
| Q26859144 | Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? |
| Q41094773 | Cardiovascular medication after cancer at a young age in Finland: A nationwide registry linkage study. |
| Q37929894 | Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia |
| Q28087637 | Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration |
| Q33777616 | Childhood B-acute lymphoblastic leukemia: a genetic update |
| Q39232609 | Childhood cancer survival in Finland (1953-2010): a nation-wide population-based study |
| Q51210641 | Childhood leukemia and lymphoma: time trends and factors affecting survival in five Southern and Eastern European Cancer Registries. |
| Q38733956 | Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report |
| Q38692261 | Childhood vaccinations and risk of acute lymphoblastic leukaemia in children |
| Q54231400 | Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers. |
| Q64121167 | Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update |
| Q24632749 | Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing |
| Q33615910 | Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries |
| Q54295812 | Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients. |
| Q34488796 | Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. |
| Q89583206 | Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia |
| Q59529214 | Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations ofIKZF1 |
| Q56797557 | Cost-effective multiplexing before capture allows screening of 25 000 clinically relevant SNPs in childhood acute lymphoblastic leukemia |
| Q34228412 | DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission |
| Q55229784 | DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia. |
| Q35129383 | DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia |
| Q53843435 | DNA methylome analysis of acute lymphoblastic leukemia cells reveals stochastic de novo DNA methylation in CpG islands. |
| Q38930022 | DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial |
| Q35545539 | Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A |
| Q37665574 | Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes |
| Q50860875 | Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. |
| Q41643837 | Detection of central nervous system involvement in childhood acute lymphoblastic leukemia by cytomorphology and flow cytometry of the cerebrospinal fluid. |
| Q37642949 | Development and use of active clinical decision support for preemptive pharmacogenomics |
| Q46730610 | Does school attendance during initial cancer treatment in childhood increase the risk of infection? |
| Q33998291 | Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group |
| Q35206306 | Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance |
| Q43455234 | Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count |
| Q35040001 | Epidemiology of therapy-related myeloid neoplasms after treatment for pediatric acute lymphoblastic leukemia in the nordic countries |
| Q36213239 | Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia |
| Q35112206 | Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group |
| Q34192080 | Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data. |
| Q51859358 | Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group. |
| Q34411660 | Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia |
| Q36547791 | Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia |
| Q57195431 | Genome-wide analysis of cytogenetic aberrations in ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia |
| Q33585130 | Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia |
| Q31170949 | Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients |
| Q53143680 | High concordance of subtypes of childhood acute lymphoblastic leukemia within families: lessons from sibships with multiple cases of leukemia. |
| Q37144889 | High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992/2000 protocols |
| Q39564925 | Hospitalisation for infection prior to diagnosis of acute lymphoblastic leukaemia in children |
| Q42237227 | Host genome variations and risk of infections during induction treatment for childhood acute lymphoblastic leukaemia |
| Q33603164 | Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model |
| Q90466697 | How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia |
| Q36980511 | Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia |
| Q40077555 | Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods |
| Q58861726 | Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols |
| Q38769075 | Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group |
| Q45777494 | Impact of hydrochloric acid instillation on salvage of infected central venous catheters in children with acute lymphoblastic leukaemia |
| Q91379893 | Improved cytogenetic characterization and risk stratification of pediatric acute lymphoblastic leukemia using single nucleotide polymorphism array analysis: A single center experience of 296 cases |
| Q34679298 | Improved prognosis for older adolescents with acute lymphoblastic leukemia. |
| Q30631947 | Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology |
| Q43789678 | Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes |
| Q40314940 | Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study |
| Q36914357 | Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy |
| Q34482019 | Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children |
| Q58861769 | Interphase fluorescent in situ hybridization deletion analysis of the 9p21 region and prognosis in childhood acute lymphoblastic leukaemia (ALL): results from a prospective analysis of 519 Nordic patients treated according to the NOPHO-ALL 2000 proto |
| Q42202408 | Late mortality among 5-year survivors of early onset cancer: a population-based register study |
| Q39571116 | Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases |
| Q38124376 | Limited impact of EU paediatric regulation on Finnish clinical trials highlights need for Nordic collaboration. |
| Q47884623 | Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL). |
| Q96588892 | MTXPK.org: A clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase |
| Q39570917 | Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? |
| Q47917289 | Maternal diabetes and risk of childhood acute lymphoblastic leukaemia in the offspring |
| Q33421300 | Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia |
| Q27023839 | Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction |
| Q39154080 | Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia. |
| Q35684384 | Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia |
| Q54314507 | MicroRNA profiling in pediatric acute lymphoblastic leukemia: novel prognostic tools. |
| Q54391883 | Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. |
| Q48125822 | Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry |
| Q39123286 | Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia |
| Q64946377 | Neurocognitive Outcome and Compensating Possibilities in Children and Adolescents Treated for Acute Lymphoblastic Leukemia With Chemotherapy Only. |
| Q50567829 | Neurocognitive Outcome in Very Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia After Treatment with Chemotherapy Only. |
| Q48057726 | Novel non-neutral mitochondrial DNA mutations found in childhood acute lymphoblastic leukemia |
| Q28543517 | Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial |
| Q36029619 | Outcomes after induction failure in childhood acute lymphoblastic leukemia |
| Q41752588 | Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia |
| Q51416496 | Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols. |
| Q58456002 | Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate |
| Q40158198 | Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials |
| Q37633532 | Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia |
| Q38956273 | Pediatric T-cell acute lymphoblastic leukemia |
| Q47908187 | Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan |
| Q36163029 | Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? |
| Q54228852 | Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer. |
| Q85397077 | Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia |
| Q36605135 | Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia |
| Q96954627 | Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate |
| Q34707213 | Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group |
| Q90099730 | Predisposition to childhood acute lymphoblastic leukemia caused by a constitutional translocation disrupting ETV6 |
| Q39272383 | Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-ALL treated according to the NOPHO ALL-1992 and ALL-2000 protocols |
| Q35976588 | Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. |
| Q48203946 | Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation |
| Q34769855 | Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia |
| Q38927735 | Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study |
| Q37815272 | Recent research advances in childhood acute lymphoblastic leukemia |
| Q89701498 | Refined detection and phasing of structural aberrations in pediatric acute lymphoblastic leukemia by linked-read whole-genome sequencing |
| Q89239783 | Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001 |
| Q61953181 | Relapsed Acute Lymphoblastic Leukemia of Childhood |
| Q36420748 | Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome |
| Q50501063 | Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. |
| Q102210959 | Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia |
| Q39785801 | Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia |
| Q46068589 | Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol |
| Q39459920 | Role of neuroimaging in children with acute lymphoblastic leukemia and central nervous system involvement at diagnosis |
| Q37252283 | Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia |
| Q37342837 | Shorter Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia: The Experience of the Prospective, Randomized Brazilian GBTLI ALL-93 Protocol |
| Q64102641 | Social Inequalities Along the Childhood Cancer Continuum: An Overview of Evidence and a Conceptual Framework to Identify Underlying Mechanisms and Pathways |
| Q40874665 | Survival From Childhood Hematological Malignancies in Denmark: Is Survival Related to Family Characteristics? |
| Q90703622 | T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol |
| Q44304631 | The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol. |
| Q40539062 | The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols |
| Q51515979 | The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial. |
| Q40097280 | The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frank |
| Q39205653 | The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). |
| Q35023231 | The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing |
| Q33674158 | Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response |
| Q55383390 | Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. |
| Q53544852 | Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. |
| Q38625509 | Transcriptome sequencing in pediatric acute lymphoblastic leukemia identifies fusion genes associated with distinct DNA methylation profiles |
| Q57283009 | Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study |
| Q40598104 | Treatment of children with acute lymphoblastic leukemia with risk group based intensification and omission of cranial irradiation: A Korean study of 295 patients |
| Q47566809 | Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia |
| Q37590225 | Trends in transfusion burden among long-term survivors of childhood hematological malignancies |
| Q44099858 | UGT1A1*28 polymorphism and acute lymphoblastic leukemia in children: a Danish case-control study |
| Q90327186 | [Effects of minimal residual disease level on day 33 of remission induction and IKZF1 genotype on the survival of children with B-lineage acute lymphoblastic leukemia] |
Search more.